InvestorsHub Logo
Followers 3
Posts 190
Boards Moderated 0
Alias Born 05/16/2013

Re: Mogwai post# 67422

Tuesday, 12/22/2015 5:45:04 PM

Tuesday, December 22, 2015 5:45:04 PM

Post# of 426270
Mogwai, you're making sense to me. There are no damages being discussed in the 1A suit - it was a pre-emptive act, so no damages are due to the plaintiff. I believe the only discussions they could be having are about advertising and promotional speech.

The only other 1A option is to make a labeling deal in exchange for dropping the suit entirely. If the FDA is concerned about making a deal with AMRN that sets a precedent, then this may be their best option, especially since they rescinded the SPA.

In the NCE suit there are no settlement discussions, period. It has been remanded to FDA for internal reassessment.

Talk of damages by anyone on this board is, as you say, totally delusional. AMRN is not interested in damages, AMRN is interested in sales and balance sheet issues, ultimately determining an appropriate buyout valuation for the company.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News